Get the Stockscreener App
30.10
0.66%
-0.20
Arrivent Biopharma Inc stock is traded at $30.10, with a volume of 608.95K.
It is down -0.66% in the last 24 hours and up +6.51% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
See More
Previous Close:
$30.30
Open:
$29.94
24h Volume:
608.95K
Relative Volume:
1.12
Market Cap:
$1.48B
Revenue:
-
Net Income/Loss:
$-166.31M
P/E Ratio:
-6.7486
EPS:
-4.4602
Net Cash Flow:
$-160.59M
1W Performance:
+6.14%
1M Performance:
+6.51%
6M Performance:
+37.13%
1Y Performance:
+68.53%
1-Day Range:
$29.23
$30.51
1-Week Range:
$28.20
$31.49
52-Week Range:
$17.00
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
30.10 | 1.48B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Dec-10-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Cantor Fitzgerald reiterates Overweight on ArriVent stock By Investing.com - Investing.com Nigeria
ArriVent BioPharma (AVBP) Stock Price, News & Analysis - MarketBeat
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Explosive 57.62% Upside Potential Fuels Investor Interest - DirectorsTalk Interviews
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating - Moomoo
Understanding the Setup: (AVBP) and Scalable Risk - news.stocktradersdaily.com
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study - TipRanks
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - qz.com
Why Did ArriVent BioPharma (AVBP) Move Today? - sahmcapital.com
ArriVent (AVBP) Trading: Posts a 2.95% Loss to $28.26 in the Current Update; Levels: Price Remains Between $26.85 Support and $29.67 ResistanceIV Spike - vinanet.vn
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Moomoo
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC - AllSci
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - The Manila Times
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026 - TradingView
ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer - Stock Titan
ArriVent BioPharma reports $49.9 million Q2 net loss - Quiver Quantitative
ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026 - Stock Titan
ArriVent BioPharma (AVBP) Edges Higher, Holding Key Support at $29.44Jelly Roll Trade - dars.gov.et
ArriVent BioPharma (AVBP) Eases 0.55% to $30.84 as Shares Remain Range-BoundBull Flag - vinanet.vn
ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday - MarketBeat
Trading the Move, Not the Narrative: (AVBP) Edition - Stock Traders Daily
ArriVent BioPharma (AVBP) Surges 6.24% to $31.49 – Biotech Momentum IntensifiesGEX Level - vinanet.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vivo Capital LLC Takes $20.44 Million Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
141,814 Shares in ArriVent BioPharma, Inc. $AVBP Bought by ADAR1 Capital Management LLC - MarketBeat
Arrivent Biopharma Inc (AVBP) Cash Flow - TradingKey
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):